Spero Therapeutics (NASDAQ:SPRO) Stock Passes Above Two Hundred Day Moving Average of $1.41

Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.41 and traded as high as $1.54. Spero Therapeutics shares last traded at $1.40, with a volume of 378,240 shares.

Wall Street Analyst Weigh In

A number of analysts have recently commented on SPRO shares. Cantor Fitzgerald restated an “overweight” rating on shares of Spero Therapeutics in a report on Thursday, April 4th. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Spero Therapeutics in a research report on Monday, March 18th.

Spero Therapeutics Price Performance

The firm has a 50-day simple moving average of $1.64 and a 200 day simple moving average of $1.41. The company has a market capitalization of $75.45 million, a PE ratio of 3.33 and a beta of 0.55.

Spero Therapeutics (NASDAQ:SPRO) last announced its earnings results on Wednesday, March 13th. The company reported $0.96 earnings per share for the quarter, beating the consensus estimate of ($0.18) by $1.14. The company had revenue of $73.52 million during the quarter, compared to the consensus estimate of $19.40 million. Spero Therapeutics had a return on equity of 38.54% and a net margin of 21.98%. Equities research analysts expect that Spero Therapeutics, Inc. will post -0.94 EPS for the current fiscal year.

Hedge Funds Weigh In On Spero Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC boosted its stake in Spero Therapeutics by 56.8% in the third quarter. Acadian Asset Management LLC now owns 272,024 shares of the company’s stock valued at $327,000 after acquiring an additional 98,485 shares during the period. XTX Topco Ltd bought a new stake in shares of Spero Therapeutics during the first quarter valued at approximately $115,000. Engineers Gate Manager LP bought a new stake in shares of Spero Therapeutics during the first quarter valued at approximately $95,000. UBS Group AG raised its holdings in shares of Spero Therapeutics by 99.4% during the fourth quarter. UBS Group AG now owns 45,682 shares of the company’s stock valued at $79,000 after buying an additional 22,774 shares during the last quarter. Finally, Two Sigma Investments LP bought a new stake in shares of Spero Therapeutics during the fourth quarter valued at approximately $69,000. 25.60% of the stock is currently owned by institutional investors and hedge funds.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.